Literature DB >> 15102007

Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No.

H Bounameaux1, P de Moerloose.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15102007     DOI： 10.1111/j.1538-7933.2004.00648.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  17 in total

1.  Evaluation of Anticoagulant Monitoring in Pediatric Patients Receiving Enoxaparin for Treatment of Venous Thrombosis.

Authors:  Jason Koury; Robert Hellinga; Jennifer Rose; Shirley Abraham; Anjali Subbaswamy
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

2.  Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients.

Authors:  Jeroen Diepstraten; Christian M Hackeng; Simone van Kralingen; Jiri Zapletal; Eric P A van Dongen; René J Wiezer; Bert van Ramshorst; Catherijne A J Knibbe
Journal:  Obes Surg       Date:  2012-02-01       Impact factor: 4.129

3.  Pulmonary embolism: current treatment options.

Authors:  Marc Meysman; Patrick Haentjens
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

Review 4.  Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.

Authors:  Virginie Siguret; Isabelle Gouin-Thibault; Pascale Gaussem; Eric Pautas
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

Review 5.  Safety profile of different low-molecular weight heparins used at therapeutic dose.

Authors:  Isabelle Gouin-Thibault; Eric Pautas; Virginie Siguret
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Prevention of venous thromboembolism in obesity.

Authors:  Andrew L Freeman; Robert C Pendleton; Matthew T Rondina
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-12

7.  Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.

Authors:  Jeroen Diepstraten; Esther J H Janssen; Christian M Hackeng; Eric P A van Dongen; René J Wiezer; Bert van Ramshorst; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2014-10-12       Impact factor: 2.953

8.  Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism.

Authors:  Brendan P McDonnell; Kate Glennon; Aoife McTiernan; Hugh D O'Connor; Colin Kirkham; Barry Kevane; Jennifer C Donnelly; Fionnuala Ni Áinle
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

9.  Diagnosis and treatment of pulmonary embolism: a multidisciplinary approach.

Authors:  Federico Lavorini; Vitantonio Di Bello; Maria Luisa De Rimini; Giovanni Lucignani; Letizia Marconi; Gualtiero Palareti; Raffaele Pesavento; Domenico Prisco; Massimo Santini; Nicola Sverzellati; Antonio Palla; Massimo Pistolesi
Journal:  Multidiscip Respir Med       Date:  2013-12-19

Review 10.  Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Authors:  Jonathan Douxfils; Anne Tamigniau; Bernard Chatelain; Catherine Goffinet; Jean-Michel Dogné; François Mullier
Journal:  Thromb J       Date:  2014-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.